leisure time -WSS

leisure time

author：knowledge 2025-08-23 08:56:52 - browse：8239

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Adele warns fans about throwing things at performers onstage

focus

Wikipedia

WSS

Health insurers' Q3 question: how much care are people getting?

City of Memphis, police chief oppose effort to delay lawsuit in Tyre Nichols case

Flu, Covid vaccination rates decline, new survey data show

Stop Congress from blocking public access to science

Flu, Covid vaccination rates decline, new survey data show

Ph.D. graduate surprised with gift registry: 'You deserve to be celebrated'

knowledge

leisure time

knowledge

Drug repurposing or repositioning? The language matters

The biotech scorecard for Q4: 16 stock

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Congress extends some pandemic preparedness programs

Peter Hotez and the public health issue of online harassment

The stability of $0 premiums in Medicare Advantage

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Novavax promises a turnaround & Lilly roils the obesity market

Nobel honors Karikó and Weissman's enduring partnership

hotspot

Nobel honors Karikó and Weissman's enduring partnership

Health insurers' Q3 question: how much care are people getting?

Pope Francis asks Church to identify 21st

6 solutions to address cancer drug shortages and others

Princess Kate attends Wimbledon with Roger Federer: See the photos

IVG is promising — but it won’t replace IVF quite yet

focus

Wikipedia

explore

focus